Jesduvroq
(Daprodustat)ApprovedSmall molecule
Jesduvroq is a small molecule that works as a HIF-PHI.[2] It is being used across 3 indications, with its most advanced program in Approved.[1]
Jesduvroq is one of 109 small molecule programs targeting Kidney Disease. It is currently in Approved.
3
Indications
17
Total Trials
2
Active Trials
108
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Jesduvroq
GGlaxo Dba Glaxosmithkline
Approved
Aranesp
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Kidney Disease10 trials
Show 7 more trials
Anemia2 trials
ART1 trial
Kidney Disease1 trial
2 more indications
Regulatory
FDA Approval Timeline[4]
Feb 1, 2023
JESDUVROQ
NDA NDA216951
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Daprodustat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- HIF-PHI[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- GGlaxo Dba Glaxosmithkline